AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aligos Therapeutics Announces Six Preclinical Presentations at 2025 International HBV Meeting: Novel Approaches and Molecular Strategies to Advance Liver and Viral Diseases.
ByAinvest
Wednesday, Sep 3, 2025 4:06 pm ET1min read
Aligos Therapeutics announced six preclinical presentations at the 2025 International HBV Meeting. The presentations cover novel approaches, molecular strategies, and insights into ALG-000184's mechanism of action. The company also showcased a new strategy to potentially cure hepatitis delta virus infection using a proprietary antisense oligonucleotide approach.
Aligos Therapeutics (Nasdaq: ALGS) has announced six preclinical presentations at the 2025 International HBV Meeting in Berlin, Germany. The presentations, which include three oral presentations and three poster presentations, showcase the company's ongoing research in liver and viral diseases, particularly focusing on ALG-000184 and a new antisense oligonucleotide (ASO) approach for hepatitis delta virus (HDV) treatment [1].The presentations highlight Aligos' commitment to advancing next-generation therapies for liver and viral diseases. Key highlights include the first presentation of ALG-000184's direct effects in reducing HBV cccDNA in preclinical settings, supporting clinical observations of HBV antigen reductions in patients [1]. Additionally, the company is expanding its pipeline with an ASO program for HDV treatment, targeting viral genome destruction as a potential cure strategy for HDV coinfection, which typically leads to more rapid disease progression [1].
The presentations will cover a range of topics, including novel approaches, molecular strategies, and insights into the mechanisms of action of ALG-000184. The oral presentations will be held on September 11, 2025, at 10:30 AM CET, while the poster presentations will be held on September 8 and 10, 2025, at various times [1].
The presentations can be found on the Posters & Presentations section of the Aligos website after the live event. For more information, please visit or follow Aligos on LinkedIn or X.
References:
[1] https://www.stocktitan.net/news/ALGS/aligos-therapeutics-announces-six-preclinical-presentations-at-the-lsn99cubm1v9.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet